These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22651555)

  • 41. Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development.
    Dingemanse J; Krause A
    Eur J Pharm Sci; 2017 Nov; 109S():S53-S58. PubMed ID: 28535992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Applications of 'decisionable' biomarkers in cardiovascular drug development.
    Krishna R; Wagner JA
    Biomark Med; 2010 Dec; 4(6):815-27. PubMed ID: 21133701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The biomarker is not the end.
    Nohaile M
    Drug Discov Today; 2011 Oct; 16(19-20):878-83. PubMed ID: 21888986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles.
    Ahn K; Luo J; Berg A; Keefe D; Wu R
    Trends Pharmacol Sci; 2010 Jul; 31(7):306-11. PubMed ID: 20488563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Models for predicting blood-brain barrier permeation.
    Nielsen PA; Andersson O; Hansen SH; Simonsen KB; Andersson G
    Drug Discov Today; 2011 Jun; 16(11-12):472-5. PubMed ID: 21513815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses.
    Kielbasa W; Stratford RE
    Drug Metab Dispos; 2012 May; 40(5):877-83. PubMed ID: 22287668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Probabilistic risk analysis: improving early drug development decision making.
    Mudd PN; Groenendaal H; Bush MA; Schmith VD
    Clin Pharmacol Ther; 2010 Dec; 88(6):871-5. PubMed ID: 20944562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Connecting the dots: role of standardization and technology sharing in biological simulation.
    Ghosh S; Matsuoka Y; Kitano H
    Drug Discov Today; 2010 Dec; 15(23-24):1024-31. PubMed ID: 20934535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings.
    Amore BM; Gibbs JP; Emery MG
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):207-18. PubMed ID: 20053166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homology modeling in drug discovery: current trends and applications.
    Cavasotto CN; Phatak SS
    Drug Discov Today; 2009 Jul; 14(13-14):676-83. PubMed ID: 19422931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.
    Baneyx G; Fukushima Y; Parrott N
    Future Med Chem; 2012 Apr; 4(5):681-93. PubMed ID: 22458685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 58. Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development.
    Nowatzke W; Cole TG; Bowsher RR
    Bioanalysis; 2010 Feb; 2(2):237-47. PubMed ID: 21083307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A challenging drug development process in the era of personalized medicine.
    Jørgensen JT
    Drug Discov Today; 2011 Oct; 16(19-20):891-7. PubMed ID: 21945860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. QT as a safety biomarker in drug development.
    Whellan DJ; Green CL; Piccini JP; Krucoff MW
    Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.